Key result
Dalteparin was similarly effective as enoxaparin for VTE prophylaxis, with no significant differences in VTE or bleeding rates, while achieving $40,788 in savings over 6 months.
Why the study?
Does dalteparin compared to enoxaparin prevent VTE in hospitalized patients at risk?
Cohort (n=3,509)
Does dalteparin compared to enoxaparin prevent VTE in hospitalized patients at risk?
A therapeutic interchange from enoxaparin to dalteparin for VTE prophylaxis in hospitalized patients maintains clinical efficacy and safety while providing cost savings.
Answers are grounded in this paper and cite their sources.
May support dalteparin interchange for VTE prophylaxis with cost savings; hypothesis-generating pending randomized confirmation.
PURPOSE: This study compared the effectiveness of a change from enoxaparin to dalteparin for the prophylaxis of patients at risk of venous thromboembolism (VTE). METHODS: A retrospective cohort study identified hospitalized patients with VTE risk admitted at Wellmont Health System between August 1, 2008 and July 31, 2009. On February 1, 2009, a therapeutic interchange from enoxaparin to dalteparin occurred. All patient records were reviewed from billing data collected 6 months prior and following conversion. Statistical tests of heterogeneity compared distributions of demography between study cohorts and Cochran tests were used to compare pre- versus postchange in the outcomes. RESULTS: A total of 3557 and 3465 patient discharges were analyzed in the 6 months prior and following the interchange, respectively. Of these discharges, 1870 were administered enoxaparin and 1639 dalteparin. VTE rates were similar between the 2 groups. Data showed no significant difference in-hospital length of stay (LOS), readmittance, and bleeding rates in the populations. The system achieved a $40 788 savings over 6 months following the conversion using approved prophylactic dosing per patient indication. CONCLUSIONS: Dalteparin is similarly effective as enoxaparin and an alternative for the prophylaxis of VTE in a hospital setting while providing cost savings.
No takes yet. Share an insight, caveat, or question.
Carson et al. (2011) conducted a cohort in Venous thromboembolism (VTE) risk (n=3,509). Dalteparin vs. Enoxaparin was evaluated on VTE rates. Dalteparin was similarly effective as enoxaparin for VTE prophylaxis, with no significant differences in VTE or bleeding rates, while achieving $40,788 in savings over 6 months.
Synapse has enriched 10 related papers. Consider them for comparative context: